Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has provided an announcement.
KYORIN Pharmaceutical Co., Ltd. has partnered with Hyfe Inc. to develop and commercialize a digital therapeutic (DTx) for chronic cough in Japan, utilizing Hyfe’s AI-powered cough monitoring technology and BCST principles. This collaboration aims to offer a new non-pharmacological treatment option for chronic cough, with KYORIN making milestone payments to Hyfe and expecting negligible impact on its fiscal performance for the year ending March 2025.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on developing high-value drugs to meet medical needs, particularly in respiratory diseases. The company is committed to its long-term vision ‘Vision 110’ to contribute to clinical development and provide new treatment options.
YTD Price Performance: -10.76%
Average Trading Volume: 84,403
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen76.96B
For a thorough assessment of 4569 stock, go to TipRanks’ Stock Analysis page.